London, 2025 — Claritas Intelligence has published its comprehensive global study on intelligent automation in healthcare, sizing the market at USD 38.6 billion in 2025 and projecting it to reach USD 111.7 billion by 2033. The base-case forecast implies a 14.2% CAGR over the 2025–2033 period, driven by accelerating deployment of RPA, AI-augmented workflow orchestration, and manufacturing process intelligence across clinical, administrative, and pharmaceutical supply-chain settings.
The single most structurally durable growth driver may be one that receives the least analyst attention: pharmaceutical manufacturing automation. The GLP-1 supply crunch, now in its third consecutive year of demand outpacing capacity for products including Ozempic and Mounjaro, has forced Novo Nordisk and Eli Lilly to expand SPPS and fill-finish lines at pace, with real-time release testing and yield optimization automation as direct operational responses. Simultaneously, FDA's approval of 17 biosimilar applications in FY2023 alone means that each 351(k) submission demands automated comparability analytics, structural similarity scoring, and reference-product lot-variability workflows. The adalimumab biosimilar class, now scaling toward 10 or more interchangeable competitors, illustrates how the documentation automation burden per manufacturer grows proportionally with market entry. On the administrative side, the Inflation Reduction Act's Maximum Fair Price framework, effective for the first 10 negotiated drugs in 2026, creates non-discretionary compliance spend: no major originator can manage gross-to-net modeling and CMS reporting overhaul at scale without intelligent automation.
North America commands approximately 41% of the global market, a share the report anchors to U.S. health expenditure running at 16.69% of GDP and USD 13,473 per capita versus a global average of 10.02% of GDP. That transaction volume in claims, prior authorizations, and pharmacy events creates a structurally large ROI case for automation vendors. Asia Pacific is the fastest-growing region; China's health spend per capita reached USD 763 in 2023, still well below developed-market levels, but rising hospital digitization budgets are compressing the automation adoption lag considerably. The vendors best positioned to capture that expansion are those with existing electronic health record integration infrastructure and local regulatory affairs capacity under China's NMPA and equivalent frameworks.
The competitive landscape spans RPA specialists and hyperscale platforms. Key vendors covered in the report include UiPath (FY2026 revenue: USD 1.61 billion), IBM (FY2025 revenue: USD 67.53 billion), GE HealthCare (FY2025 revenue: USD 20.63 billion, with its Edison AI platform cited as a differentiator in radiology-adjacent automation), Automation Anywhere, Microsoft, Siemens Healthineers, Philips Healthcare, Oracle Health, Google Cloud Healthcare AI, AWS HealthLake, Veeva Systems, and Blue Prism (now under SS&C Technologies). The report's contrarian finding is that administrative RPA, while growing in absolute terms, is the most margin-compressed segment as hyperscalers bundle equivalent functionality into broader platform contracts. Durable value accrues to players that own the clinical data layer.
"Pharmaceutical manufacturing process intelligence, covering real-time release testing, PAT integration, and continuous flow monitoring, is the most underpenetrated sub-segment relative to its total addressable market. Most coverage focuses on prior-auth bots and NLP triage because the deal flow is visible and the buyers are familiar. The harder, more defensible, and ultimately more valuable automation opportunity is inside the plant, not the revenue cycle office." — Ananya Sharma, Senior Analyst, Claritas Intelligence
The report also notes that academic output on intelligent automation in healthcare has generated 62,560 indexed works since 2023, a knowledge base moving faster than most vendor product cycles and shortening the path from research to clinical protocol integration for vendors with strong academic partnerships.
About Claritas Intelligence: Claritas Intelligence is a global market intelligence publisher delivering primary-research-grounded forecasts, competitive landscaping, and strategic analysis across technology, healthcare, and industrial sectors. Our models are built on triangulated primary data, regulatory filings, and macroeconomic indicators.
The full analysis, including segmentation, regional breakdowns, forecasts, and company profiles, is available in the Intelligent Automation in Healthcare Market Report.
“The global intelligent automation in healthcare market is projected to grow from USD 38.6 billion in 2025 to USD 111.7 billion by 2033 at a 14.2% CAGR, per Claritas Intelligence's latest report.”
Ananya Sharma
Senior Research Analyst – Healthcare & Life Sciences